IP Library Granted Patent US 7,332,290
Granted Patent B2
US 7,332,290 · App. 10/909,035 · Granted Feb 19, 2008

Dectection of AMACR cancer markers in urine

Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,332,290
App. No.
10/909,035
Granted
Feb 19, 2008
Kind
B2
Abstract

The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. The present invention also provides novel markers useful for the diagnosis, characterization, and treatment of prostate cancers. In particular, the present invention provides methods and compositions for the detection of α-methylacyl-CoA racemase (AMACR) in the urine as a marker for prostate cancer detection.

Claims (13)

1. A method of detecting the presence or absence of prostate cancer in a subject, comprising:

a) providing

i) urine from a subject;

ii) a reagent for detecting α-methylacyl-CoA racemase in said urine; and

b) contacting said urine with said reagent under conditions such that said reagent detects the presence or absence of α-methylacyl-CoA racemase in said urine;

c) determining the presence or absence of prostate cancer in said subject based on said presence or absence of α-methylacyl-CoA racemase in said urine.

2. The method of claim 1 , wherein level of said α-methylacyl-CoA racemase in said urine is determined.

3. The method of claim 2 , wherein a minimum threshold level of expression of α-methylacyl-CoA racemase is set to 1, where 0 is absence of α-methylacyl-CoA racemase and 4 is highest level expression.

4. The method of claim 3 , wherein the presence of said α-methylacyl-CoA racemase in said urine at a level above said minimum threshold level is indicative of a diagnosis of prostate cancer in said subject.

5. The method of claim 1 , wherein said reagent is an antibody.

6. The method of claim 5 , wherein said antibody is selected from the group consisting of a single chain antibody, an Fab, and an epitope-binding fragment.

7. The method of claim 1 , wherein said reagent comprises a label.

8. The method of claim 7 , wherein said label is selected from the group consisting of a radioactive label, a fluorescent label, a chemiluminescent label, and a bioluminescent label.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 19, 2010
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024704/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2005
From: RUBIN, MARK A.; CHINNAIYAN, ARUL M.; LAXMAN, BHARATHI; SREEKUMAR, ARUN
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 016310/0405 →
Continuity (4)
Continuation In Part 1021012000 · Aug 1, 2002
Provisional Application 6033446800 · Nov 15, 2001
Provisional Application 6030958100 · Aug 2, 2001
Related Publication 20050136493A1 · Jun 23, 2005